VPC-14449 is a selective small molecule inhibitor targeting the DNA-binding domain (DBD) of the androgen receptor (AR). It is utilized in prostate cancer research to study AR signaling and has demonstrated activity in disrupting AR-DNA interactions in both cellular and animal models.